These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 28057739)

  • 1. Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in
    Chen CC; You JY; Lung J; Huang CE; Chen YY; Leu YW; Ho HY; Li CP; Lu CH; Lee KD; Hsu CC; Gau JP
    Haematologica; 2017 Mar; 102(3):509-518. PubMed ID: 28057739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F-positive myeloproliferative neoplasm.
    Martin SE; Sausen M; Joseph A; Kingham BF; Martin ES
    Cancer Genet; 2012 Jun; 205(6):295-303. PubMed ID: 22749035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of HMGA2 in myeloproliferative neoplasms].
    Ikeda K
    Rinsho Ketsueki; 2018; 59(10):2067-2074. PubMed ID: 30305510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
    Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
    Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms.
    Ikeda K; Ogawa K; Takeishi Y
    Fukushima J Med Sci; 2012; 58(2):91-100. PubMed ID: 23237864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
    Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
    Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
    Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
    Oh ST; Gotlib J
    Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XIAP 3'-untranslated region serves as a competitor for HMGA2 by arresting endogenous let-7a-5p in human hepatocellular carcinoma.
    Wu WY; Tao SQ; Wang XN; Lobie PE; Wu ZS
    Tumour Biol; 2017 Jul; 39(7):1010428317719578. PubMed ID: 28691642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways.
    Petiti J; Rosso V; Lo Iacono M; Panuzzo C; Calabrese C; Signorino E; Pironi L; Cartellà A; Bracco E; Pergolizzi B; Beltramo T; Fava C; Cilloni D
    J Cell Mol Med; 2019 Jun; 23(6):4349-4357. PubMed ID: 31033209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms.
    Harada-Shirado K; Ikeda K; Ogawa K; Ohkawara H; Kimura H; Kai T; Noji H; Morishita S; Komatsu N; Takeishi Y
    Br J Haematol; 2015 Feb; 168(3):338-49. PubMed ID: 25236537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Let-7a suppresses glioma cell proliferation and invasion through TGF-β/Smad3 signaling pathway by targeting HMGA2.
    Li Y; Zhang X; Chen D; Ma C
    Tumour Biol; 2016 Jun; 37(6):8107-19. PubMed ID: 26715270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
    Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
    Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanism of targeted inhibition of HMGA2 via miRNAlet-7a in proliferation and metastasis of laryngeal squamous cell carcinoma.
    Ma LJ; Wu J; Zhou E; Yin J; Xiao XP
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32432318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hmga2 promotes the development of myelofibrosis in Jak2
    Dutta A; Hutchison RE; Mohi G
    Blood; 2017 Aug; 130(7):920-932. PubMed ID: 28637665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.